102 results about "Tumor reduction" patented technology

Provided are compositions and methods of use for insect cells comprising baculovirus encoding non-surface expressed proteins and peptides. The claimed invention particularly relates to compositions comprising insect cells containing baculovirus that express cytokines. Such compositions may be administered by, for example, direct intratumoral injection into tumors in mammals, resulting in tumor reduction or recission. Another aspect of the claimed invention concerns methods of promoting resistance to the reoccurence of tumors in mammals who have undergone such tumor recission. In a specific aspect of the claimed invention, the mammals are human subjects presenting with various forms of cancer.

The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides. Tumor-bearing patients can be immunized with the recombinant influenza viruses alone, or in combination with another treatment, to induce an immune response that leads to tumor reduction. The recombinant viruses can also be used to vaccinate high risk tumor-free patients to prevent tumor formation in vivo.

The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides. Tumor-bearing patients can be immunized with the recombinant influenza viruses alone, or in combination with another treatment, to induce an immune response that leads to tumor reduction. The recombinant viruses can also be used to vaccinate high risk tumor-free patients to prevent tumor formation in vivo.

A method for selecting a female breast cancer patient for AT1 receptor antagonist therapy comprises (a) determining whether the cancer comprises a tumor that is ER+ and / or PR+; and (b) selecting the patient for AT1 receptor antagonist therapy only if the cancer is determined to comprise an ER+ and / or PR+ tumor. A method for treating breast cancer in a female patient further comprises (c) administering to the patient, if so selected, an AT1 receptor antagonist according to a regimen effective to reduce growth, invasiveness and / or metastasis of the tumor.

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to said vectors for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing CD40L in a cell and increasing tumor specific immune response and apoptosis in a subject, as well as to uses of the oncolytic adenoviral vector of the invention for producing CD40L in a cell and increasing tumor specific immune response and apoptosis, while decreasing tumor-associated immunosuppression, in a subject.

The invention provides a method to reduce the rate of tumor metastasis and tumor recurrence after surgery and chemotherapy and radiotherapy by removing circulating tumor cells (CTC) in the blood after surgery and chemotherapy and radiotherapy by means of specificity, thereby improving the survival rate of cancer patients. The invention provides a method and a system for removing tumor cells. Patients ' blood is guided out to pass through a container, an antibody or a ligand capable of combining with the specificity of the tumor cells is fixed on a solid-phase carrier in the container, whne the patients ' blood passes through the container, the tumor cells can be absorbed by the specificity to be unable to flow back to patients ' blood, and then the tumor cells are removed from the blood to reduce the recidivation of tumor patients and to prolong their survival rate. The removed tumor cells can be washed out from the solid-phase carrier for counting. The invention further provides a method to remove pathogen from blood. Blood is withdrawn from a patient and its plasma and cellular components are separated by means of a plasma separator under the effect of a blood pump, the plasma portion inactivates the pathogen in the blood via a pathogen inactivating device, flows back to extracorporeal circulation passage to merge with the cellular components and then is returned to the patient. The method adopts a physical means, so that side effects can be reduced. The device is simple in structure and can be connected with other blood purification devices.

Aplidine demonstrates considerable promise in phase (I) clinical trials for treatment of tumors, and various dosing regimes are given. Tumor reduction has been observed in several tumor types including renal carcinoma, colorectal cancer, lung carcinoid, medullary thyroid carcinomas and melanoma. It has also been found that aplidine has a role in inhibiting angiogenesis, complementing the anti-tumor activity.

The present invention relates to tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. More precisely, the present invention relates to tricyclic derivatives as colchicine derivatives, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. Tricyclic derivatives of the present invention show very powerful cytotoxici ty to cancer cell lines but were much less toxic than colchicine or taxol, confirmed through animal toxicity test. Tricyclic derivatives of the inventi on also decrease the volume and weight of a tumor and have a strong angiogenesi s inhibiting activity in HUVEC cells. Thus, tricyclic derivatives of the prese nt invention can effectively be used as an anticancer agent, anti-proliferation agent and an angiogenesis inhibitor.

Compositions of matter, of production, and treatment modalities are disclosed for the prevention and / or therapeutic reduction of tumors through induction of immunity against tumor associated fibroblasts and components of tumor microenvironment. In one embodiment of the invention, placentally derived fibroblast cells are cultured under conditions replicating tumor microenvironment. Expression of CD248 on said cultured fibroblasts is used as a marker of effective manipulation. Cells expressing CD248 are utilized a immunogens for stimulation of immunity towards cancer associated fibroblastic cells.

The present invention relates to a composition for preventing or treating cancer, which contains, as an active ingredient, a Panax ginseng cambium-derived cell line including wild ginseng or ginseng; a lysate thereof; an extract thereof; or a culture medium thereof.The cell line according to the present invention, a lysate thereof, an extract thereof and a culture medium thereof are derived from a natural and have minimized side effects compared to the conventional therapeutic drugs, and thus are safe for the human body. Also, they are involved directly in the growth of cancer to induce cancer cell death effectively, and show anticancer activity of inhibiting or reducing the formation of tumor or the growth of tumor, Accordingly, the cell line, the lysate thereof, the extract thereof and the culture medium thereof are useful for the prevention, treatment and alleviation of cancer.

The invention provides methods and compositions for reducing the number of cancer stem cells in a mixed population of differentiated cells (for example, cancer cells) and cancer stem cells. The cancer stem cells, if present, can be more resistant to traditional drug-based therapies and can provide a source for new, differentiated cancer cells associated with the development of drug-resistance and more aggressive phenotypes. When combined with traditional cancer therapies, for example, drug-based therapies, the methods and compositions of the invention provide a more effective way for treating cancer and can provide a model system for developing new cancer therapies and new treatment modalities.

A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. A representative of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide (CCDTHT) was shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. CCDTHT had even greater effects on tumor volume, body weight, and survival when administered to animals together with the human protein placental alkaline phosphatase. These trialkylammonium group-containing compounds and alkaline phosphatases, particularly in combination with each other and other therapies, may be used to treat cancer and other cell proliferative diseases.

The invention discloses a photoacoustic imaging surgical navigation platform for guiding tumor excision, which comprises photoacoustic imaging equipment, and the photoacoustic imaging equipment comprises a main body, a probe and an image display. The invention discloses the photoacoustic imaging operation navigation platform for guiding tumor excision, and high-frame-rate photoacoustic images andultrasonic images can be provided; deep tissue tumors are visualized in real time; the position of the tumor can be positioned and a tumor boundary is accurately drawn; meanwhile, an aseptic scalpel can be visually improved through photoacoustic imaging; simultaneous development of the tumor and the scalpel under photoacoustic imaging is realized, and the focus can be thoroughly excised by directly viewing the tumor boundary without missing or mistaken cutting, the technology can be used for tumor positioning, boundary defining and accurate excision in the operation process, accurate intraoperative guidance is provided for tumor surgeons, the incompleteness of intraoperative tumor excision is reduced, the thorough excision rate is increased, normal tissue is reserved to the maximum extent,tumor recurrence is reduced, and the survival rate is increased.

The present invention relates to compositions and methods for removing tumor cells in a patient with at least one tumor site. More specifically, the method comprises contacting in vivo at least one tumor cell within the tumor with a cytolytic agent under cytolytic conditions to form a treated tumor; and applying a sufficient in vivo stimulus to the treated tumor to form a stimulated tumor. tumor. Compositions and methods for shrinking local tumors or distant metastatic tumors, or both, in a patient are included. In a preferred aspect, the method of shrinking a tumor in a patient comprises contacting stimulated tumor cells with a cytolytic agent in vivo. Stimulation directed at the tumor cells can increase the levels of chaperone proteins within the tumor cells. The combination of cytolytic agents and tumor cell stimulation, wherein the stimulation is applied simultaneously or sequentially, results in shrinkage of the directly treated tumor. Furthermore, distant or metastatic tumors not directly treated are also reduced by introducing a cytolytic agent to stimulated tumor cells within the first tumor ("treated tumor" or "localized tumor"). In order to optimize the effect of tumor shrinkage, the preferred method steps comprising introducing a cytolytic agent and stimulating the tumor cells are repeated.

The invention belongs to the technical field of immunotherapy, and particularly relates to a bispecific chimeric antigen receptor capable of recognizing CD19 and CD123 tumor associated antigens, an expression vector of the chimeric antigen receptor, a CAR-T cell and application of the CAR-T cell. The bispecific chimeric antigen receptor can recognize double targets of CD19 and CD123, not only can be effectively expressed in T lymphocytes, but also can reduce the probability of tumor immune escape and reduce the tumor recurrence rate after CAR-T treatment.

Aplidine demonstrates considerable promise in phase (I) clinical trials for treatment of tumours, and various dosing regimes are given. Tumor reduction has been observed in several tumour types including renal carcinoma, colorectal cancer, lung carcinoid, medullary thyroid carcinomas and melanoma. It has also been found that aplidine has a role in inhibiting angiogenesis, complementing the anti-tumour activity.

The invention discloses siRNA capable of specially inhibiting expression of an LAMB1 gene, a recombinant vector of the siRNA and application of the siRNA in reversing ovarian cancer taxol resistance, and belongs to the technical field of molecular biology and biological medicine. The siRNA comprises a sense strand and an antisense strand, the sense strand is 5'-UGUUUGAAAGCCGAAUCUGCG-3', and the antisense strand is 5'-CAGAUUCGGCUUUCAAACAAA-3'. According to the siRNA, mRNA and protein expression of the LAMB1 gene in a cancer cell can be inhibited specially and efficiently, proliferation of the cancer cell is reduced, cell apoptosis is increased, the invasiveness and migration capability of the cancer cell is reduced, and moreover, the resistance of an ovarian cancer cell to taxol can be reversed effectively. The invention further provides the application of the siRNA and the recombinant vector thereof in preparing medicines treating an ovarian cancer, a hepatocellular cancer, a colorectal cancer, a malignant glioma, a prostatic cancer or a gastric cancer and medicines reversing the ovarian cancer taxol resistance.

The invention provides a pulse generating circuit, a pulse generating device and a pulse generation method. The pulse generating circuit comprises a charge storing unit, a voltage dividing unit and a pulse generating unit; the charge storing unit is electrically connected with a power supply module; the voltage dividing unit is electrically connected with the charge storing unit through an input end, electrically connected with a control module through an output end, and used for feeding back electric signals of the charge storing unit to the control module; the pulse generating device is electrically connected with the charge storing unit through an input end, electrically connected with the control module through a control end, and used for outputting pulses according to control signals of the control module; and the control signals are generated based on the electrical signals. The pulse generating circuit can ensure more uniform electric field distribution in cells and tissues to achieve more thorough tumor ablation effect, thereby reducing tumor recurrence; and meanwhile, the pulse generating circuit can greatly increase current density threshold value for causing muscle contraction so as to reduce muscle contraction strength to relieve pain of a patient in the treatment process and reduce electrode needle displacement, thereby ensuring more accurate control over the ablation area.

The invention relates to calcium carbonate based compound micro particles and preparation and application thereof. The calcium carbonate based compound micro particles disclosed by the invention comprise calcium carbonate and a macromolecule stable layer, wherein the macromolecule stable layer comprises amphipathic molecules and / or hydrophilic molecules. The invention further discloses applicationof the calcium carbonate based compound micro particles to preparation of one or more of an adjuvant, a chemotherapy enhancing adjuvant, a radiotherapy enhancing adjuvant and a radiofrequency ablation treatment adjuvant for tumor immnuotherapy. The calcium carbonate based compound micro particles disclosed by the invention have an excellent effect of regulating a tumor slight acid environment, can reduce content of immunosuppressive cells in tumor, increase content of immune cells capable of killing the tumor and promote polarization of tumor-associated macrophages from the M2 type to the M1type, effectively turns the tumor immunosuppression micro environment, activate antitumor immunity, and can enhance a suppression effect of various treatment means of immunotherapy, chemotherapy, radiotherapy, radiofrequency ablation treatment and the like on tumor growth.

The invention relates to the technical field of a nano material, and particularly relates to gold silver sulfide protein composite hydrogel and a preparation method and application thereof. The hydrogel provided by the invention comprises a protein with negative charges, photo-thermal heterogeneous nanoparticles with positive charges and chitosan (CS) with positive charges, wherein the photo-thermal heterogeneous nanoparticles with the positive charges are gold silver sulfide hybrid nanoparticles (Ag3AuS2NPs); and the protein with the negative charges is a compound protein (VPGEG) 72-GFP of an elastin-like protein and a green fluorescent protein. The hydrogel has injectability, an efficient photo-thermal treatment effect and biocompatibility, and the photo-thermal efficiency can reach 39.0%. The hydrogel is uniformly dispersed around a tumor in a peritumoral injection manner, and then photo-thermal conversion is generated through irradiation, so that effective killing on the tumor is implemented, and tumor recurrence is reduced.

Apparatuses and methods for treating tumors. A method of treatment may include reducing the microvasculature of a region between a tumor and a lumen through or adjacent to the tumor (e.g., by administering radiation therapy targeting the tumor), isolating a segment of a lumen proximate to the tumor, and administering a dose of a chemotherapeutic agent to the segment.

Described are antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and / or myeloid-derived suppressor cells (MDSCs), to expand T effector cell populations or function, and to reduce the proliferation of, or directly kill, tumor cells, such as tumor cells that express TNFR2 antigen. The polypeptides, such as antibodies and antigen-binding fragments thereof, are TNFR2 antagonists, such as dominant TNFR2 antagonists. The polypeptides can be used to suppress the T-reg- or MDSC-mediated deactivation of tumor reactive T lymphocytes, expand populations of tumor-reactive cytotoxic T cells, and / or to directly kill TNFR2+ tumor cells. The antagonistic TNFR2 polypeptides described herein can be used to treat a wide variety of cancers and infectious diseases.

The invention relates to the technical field of biological cells, in particular to an immune cell and application thereof. A chimeric antigen receptor is expressed on the cytomembrane of the immune cell, and in addition, an immune checkpoint antibody protein fused with a cytokine receptor is also expressed on the cytomembrane. The expression CAR cell of the immune checkpoint antibody protein fused with the cytokine receptor is also expressed on the cytomembrane; through the immune checkpoint antibody protein which is fused with the cytokine receptor and is expressed on the immune cytomembrane, two negative feedback approaches PD-1 and CTLA-4 are blocked so as to weaken negative regulation and control of a tumor microenvironment for the immune cell, reduce exhaustion of the immune cell, enhance the tumor killing function of the immune cell and reduce inhibition of the immune cell by the tumor microenvironment; and in addition, through binding with the cytokine receptor, corresponding JAK and STAT signal channels are activated, and the cells are induced to secrete various active substances, including IFN-[gamma], perforin, granzyme and the like so as to inhibit growth of tumor cells, enhance an anti-tumor capacity, reduce the exhaustion and reduce the inhibition of the immune cell by the tumor microenvironment.

The invention belongs to the field of chemical medicine, and particularly relates to a small molecule compound having an IDO1 / TDO double target, wherein the general formula is defined in the specification. According to the present invention, the embodiment schemes prove that the small molecule compound can simultaneously inhibit two enzymes IDO1 and TDO so as to reduce the immune evasion of tumorcells, achieve self-cure of tumor diseases, achieve good medicinal potential and provides new potential choice for clinical medication; the preparation method has characteristics of simpleness, mild reaction condition, convenient operation, convenient control, low energy consumption, high yield and low cost, and is suitable for industrial production; and the prepared compound has advantages of high biological activity, strong selectivity to tumor cells, remarkable drug-like properties, and good application prospects in the pharmaceutical industry.

The invention provides a group of antitumor T lymphocytes. The group of antitumor T lymphocytes are used for representing the following five types of lymphocyte membrane molecules to a certain extent: human leukocyte differentiation antigens CD3, human leukocyte differentiation antigens CD4, human leukocyte differentiation antigens CD8, human Alpha Beta T cell receptors and human Gamma Delta T cell receptors, thereby inhibiting the proliferation of breast cancers and hepatoma cell lines, inducing the apoptosis of cancer cells as well as inhibiting the growth of the in-vivo tumors of tumor-bearing mice suffering from the hepatoma and the breast cancers. If the antitumor T lymphocytes provided by the invention are matched with the traditional surgery, chemotherapy and radiation therapy, a small quantity of residues and diffused tumor cells are removed and killed in a biological therapy mode after a large quantity of tumor cells are removed by the conventional therapy method, thereby improving and consolidating the tumor therapy and reducing the tumor relapse.

The invention discloses an application of a polypeptide PTPR in preparation of a tumor immunotherapy drug, and particularly relates to a novel polypeptide designed by using a competitive inhibition principle on the basis of an amino acid sequence of a PD-L1 stability functional segment regulated by TMUB1. The polypeptide can enhance ubiquitination of the intracellular PD-L1 and promote degradation and removal of the PD-L1; by inhibiting stability regulation and control of TMUB1 to PD-L1, drug resistance of tumor cells to antibodies is inhibited, the problems that medication time is prolonged, the curative effect is reduced and the like are avoided, PD-L1 protein is induced to be degraded through proteasome so as to reduce the abundance of PD-L1 on the surfaces and inside the tumor cells, and the function of promoting tumor immune escape by the PD-L1 is fundamentally inhibited.